Dupixent® (dupilumab) to Treat Chronic Spontaneous Urticaria (CSU) Advances in EU with Positive CHMP Opinion

Recommendation for adults and adolescents based on Phase 3 trials showing Dupixent significantly reduced itch and hives at 24 weeks compared to ...

Press Release: Sanofi and Regeneron’s Dupixent to treat chronic spontaneous urticaria advances in EU with positive CHMP opinion

Sanofi and Regeneron’s Dupixent to treat chronic spontaneous urticaria advances in EU with positive CHMP opinionRecommendation for adults and ...

Sanofi (SAN:CA) Presents at Bank of America Global Healthcare Conference 2025 Transcript

Bank of America Global Healthcare Conference 2025 September 23, 2025 4:50 AM EDTCompany ParticipantsPaul Hudson - CEO ...
TipRanks on MSN

Regeneron, Sanofi announce CHMP opinion recommending Dupixent approval

Regeneron Pharmaceuticals (REGN) and Sanofi (SNY) announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use has adopted an opinion recommending the approval of ...

Teva Pharmaceutical Industries Limited (TEVA) Presents at Bank of America Global Healthcare Conference 2025 Transcript

Get going with our next company presenter at the BofA Healthcare Conference here in London. Pleased to be introducing Teva Pharmaceuticals and CEO, Richard Francis. My name is Jason Gerberry. I'm one ...
TipRanks on MSN

Sanofi’s Dupixent Advances in EU with Positive CHMP Opinion

An announcement from Sanofi ( ($SNY) ) is now available. On September 22, 2025, Sanofi and Regeneron announced that their drug Dupixent received a ...